You are on page 1of 2

University of Minnesota Department of Psychiatry Interventional Drug Studies with

Suspended Enrollment
Currently Active Studies
N-Acetylcysteine in the Treatment of Deliberate Self Harm in Adolescents: An Open Label Pilot
Study
PIs: Kathryn Cullen, Michael Miller
Postnatal Choline Supplementation in Children with Prenatal Alcohol Exposure
PI: Jeffrey Wozniak
An Adaptive Treatment Strategy for Adolescent Depression
PI: Meredith Gunlicks-Stoessel
A Personalized Approach to Achieving a Sustained Response to Treatment for Adolescent
Depression
PI: Meredith Gunlicks-Stoessel
Sex Differences & Progesterone's Effect on Impulsivity and Cocaine Cessation
PI: Sheila Specker
A Phase II, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to
Evaluate Efficacy and Safety of RO4917838 in Combination with Selective Serotonin Receptor
Inhibitors in Patients with Obsessive Compulsive Disorder
PI: Suck Kim
Intranasal Oxytocin for the Treatment of Children and Adolescents with Autism Spectrum
Disorders (ASD)
PI: Suma Jacob
Single Dose Intranasal Oxytocin (IN-OT) Versus Placebo in Autism: Examining the Cognitive
Effects
PI: Suma Jacob
A Multi-Center, Randomized, Double-Blind, 12-Week, Parallel Group, Placebo-Controlled Proof of
Concept Study to Investigate the Efficacy and Safety of RO5285119 in Individuals with Autism
Spectrum Disorders (ASD)
PI: Suma Jacob
Promoting Social Perceptual Learning with Oxytocin in Autism
PI: Suma Jacob
Open-Label Intravenous Subanesthetic Ketamine for Adolescents with Treatment-Resistant
Depression
PI: Kathryn Cullen

An Adaptive, Phase IIB/III, Double-Blind, Randomized, Placebo-Controlled, Multi-Center Study of
the Safety and Efficacy of Naben¿ (Sodium Benzoate), A Damino Acid Oxidase Inhibitor, as an
Add-Om Treatment for Schizophrenia in Adolescents
PI: Sanjiv Kumra
Clozapine for Cannabis Use in Schizophrenia
PI: S. Charles Schulz
A Randomized, Double-Blind, Placebo-Controlled Study of SD-809 (Dutetrabenazine) for the
Treatment of Moderate to Severe Tardive Dyskenisia and an Open-Label, Long-Term Safety Study
of SD-809 (Dutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
PI: Stephen Olson
Studies Awaiting Approval
An Exploratory, Multicenter, Single-blind, fMRI Study of Fixed-dose Brexpiprazole (OPC-34712)
(2mg/day tablets) as an Adjunctive Treatment in Adults with Major Depressive Disorder and
Irritability.
PI: Barry Rittberg
A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of SD-809
(Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia
PI: Stephen Olson
A Cluster Randomized, Multi-center, Parallel-group, Rater-Blind Study Comparing Treatment with
Aripiprazole Once Monthly and Treatment as Usual on Effectiveness in First Episode and Early
Phase Illness in Schizophrenia
PI: S. Charles Schulz